Abstract CT029: Safety and clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 trial in subjects with recurrent or advanced uterine serous carcinoma (USC)Funda Meric‐Bernstam, Anthony W. Tolcher, Ruth Lambersky et al.|Cancer Research|2022Cited by 16